Latest Period
Q2 2026
Security Snapshot
Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (ZBIO) Institutional Ownership
CUSIP: 98937L105
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
143
Shares (Excl. Options)
61,237,636
Price
$25.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ZBIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 61,237,636
- Total 13F value
- $1,547,825,294
- Portfolio coverage rank
- 0%
- Share change
- +3,115,027
- Value change
- +$88,291,573
- Number of holders
- 143
- Shares outstanding
- 66,232,735
- SEC-reported price per share
- $31.09
- Insider filing price
- $31.09
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ZBIO - Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 98937L105.
- 143 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 138 to 143 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,112,055,053 to $1,547,825,294.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 143 institutions filings for Q2 2026.
Security key
98937L105
Latest holder period
Q2 2026
13F holders
143
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
ZBIO full holder history
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Zenas BioPharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98937L105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ZBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +30% | $277,876,336 | +$109,228,632 | 7,652,255 | +65% | FMR LLC | 31 Dec 2025 |
| SR ONE CAPITAL MANAGEMENT, LLC | 7.7% | -19% | $148,264,043 | 5,037,854 | 0% | SR One Capital Management, LLC | 13 Aug 2026 | |
| InnoCare Pharma Inc. | 9.4% | $111,026,500 | 5,000,000 | InnoCare Pharma Inc. | 07 Oct 2025 | |||
| Enavate Sciences GP, LLC | 4.9% | -34% | $100,899,610 | -$20,947,043 | 3,245,404 | -17% | Enavate Sciences GP, LLC | 19 Aug 2026 |
| MOULDER LEON O JR | 5.1% | +6% | $67,767,315 | +$4,017,777 | 3,220,880 | +6.3% | MOULDER LEON O JR | 29 Apr 2026 |
| Longitude Capital Partners IV, LLC | 4.9% | $58,425,578 | 2,631,522 | Patrick G. Enright | 09 Oct 2025 | |||
| Novo Holdings A/S | 4.7% | -12% | $44,400,000 | -$4,772,267 | 2,000,000 | -9.7% | Novo Holdings A/S | 30 Sep 2025 |
As of 30 Jun 2026, 143 institutional investors reported holding 61,237,636 shares of Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (ZBIO). This represents 92% of the company’s total 66,232,735 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 9,506,701 | +4.7% | 0.01% | $241,280,071 |
| SR One Capital Management, LP | 7.6% | 5,037,854 | 0% | 12% | $127,860,735 |
| NEA Management Company, LLC | 6.1% | 4,023,219 | 0% | 6.4% | $102,109,298 |
| ENAVATE SCIENCES GP, LLC | 5.9% | 3,919,159 | 0% | 29% | $99,468,255 |
| FEDERATED HERMES, INC. | 4.7% | 3,116,805 | -0.33% | 0.11% | $79,104,511 |
| BlackRock, Inc. | 4.1% | 2,686,225 | +32% | 0% | $68,176,389 |
| Capital International Investors | 3.8% | 2,502,912 | +2.8% | 0.01% | $63,523,907 |
| Polar Capital Holdings Plc | 3.6% | 2,412,772 | -5.3% | 0.17% | $61,236,153 |
| Royalty Pharma Sub-Manager, LLC | 3.6% | 2,388,150 | 0% | 25% | $60,611,247 |
| Fairmount Funds Management LLC | 3.6% | 2,359,025 | 0% | 4% | $59,872,055 |
| STATE STREET CORP | 3.1% | 2,055,100 | +40% | 0% | $52,158,438 |
| NVP ASSOCIATES, LLC | 2.8% | 1,838,482 | 0% | 14% | $46,660,673 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4% | 1,593,819 | +28% | 0.01% | $40,451,126 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2% | 1,354,864 | +8.8% | 0% | $34,386,448 |
| BANK OF AMERICA CORP /DE/ | 1.9% | 1,231,159 | +217% | 0% | $31,246,815 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 1,226,928 | +243% | 0% | $31,141,000 |
| ALLIANCEBERNSTEIN L.P. | 1.7% | 1,103,388 | 0% | 0.01% | $21,571,235 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 882,654 | +35% | 0% | $22,406,450 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 815,150 | +196% | 0.02% | $20,688,507 |
| EcoR1 Capital, LLC | 1.2% | 789,500 | 0% | 0.99% | $20,037,510 |
| MILLENNIUM MANAGEMENT LLC | 1% | 660,470 | +39% | 0.01% | $16,762,729 |
| Woodline Partners LP | 0.89% | 590,539 | +0% | 0.05% | $14,987,880 |
| Balyasny Asset Management L.P. | 0.87% | 576,717 | -14% | 0.03% | $14,637,077 |
| ArrowMark Colorado Holdings LLC | 0.87% | 573,318 | -13% | 0.61% | $14,550,811 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.77% | 509,789 | -55% | 1.4% | $12,938,445 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 61,237,636 | $1,547,825,294 | +$88,291,573 | $25.38 | 143 |
| 2026 Q1 | 56,887,525 | $1,112,055,053 | +$218,738,134 | $19.55 | 138 |
| 2025 Q4 | 41,561,367 | $1,504,857,337 | +$255,199,550 | $36.31 | 118 |
| 2025 Q3 | 34,774,383 | $771,813,059 | +$23,276,708 | $22.20 | 78 |
| 2025 Q2 | 34,055,191 | $329,977,952 | +$15,611,752 | $9.69 | 72 |
| 2025 Q1 | 32,489,801 | $256,715,238 | +$5,759,402 | $7.90 | 67 |
| 2024 Q4 | 31,699,756 | $259,632,936 | +$20,083,837 | $8.19 | 65 |
| 2024 Q3 | 24,771,152 | $418,526,187 | +$418,475,122 | $16.92 | 44 |